NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The Global Rem sleep behavior disorder market size is estimated to grow by USD 438.6 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 6.7% during the forecast period. Rising prevalence of neurological disorders is driving market growth, with a trend towards integration of AI and ML into rem sleep behavior disorder detection.
However, regulatory complexities in rem sleep behavior disorder treatment poses a challenge.Key market players include 21st Century HealthCare Inc, Aurobindo Pharma USA Inc., Bluebonnet Nutrition Corp.
, Cambrex Corp., Carlson Laboratories Inc., Church and Dwight Co.
Inc., F. Hoffmann La Roche Ltd.
, GNC Holdings LLC, Jarrow Formulas Inc., Life Extension Foundation Buyers Club Inc., Lupin Ltd.
, Natrol LLC, NOW Health Group Inc., Pharmavite LLC, Solgar Inc., Sun Pharmaceutical Industries Ltd.
, Swanson Health Products Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd.
, and Zydus Lifesciences Ltd.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered End-user (Hospitals, Clinics, and Home healthcare), Type (Clonazepam, Melatonin, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)) Re.
